By Takushi Nagai, Komei Shirabe, Toshitsugu Yubisui, and Masazumi Takeshita A patient in Kurobe, Japan, was previously reported to have a new class of hereditary methemoglobinemia, type 111. In this patient, NADH cytochrome b5 reductase deficiency was observed in lymphocytes and platelets as well as in erythrocytes, but this was not associated with mental retardation. A base change was identified in the gene for NADH cytochrome b5 reductase, causing an amino acid substitution from Leu-I 48 to Pro. In the present study, the mutant enzyme (Leu-1 4 8 -P Pro) was expressed in Escherichia coli, purified, and characterized. The mutant enzyme retained about 60% of the catalytic activity of the wild type, but was remarkably heat unstable. By incubating the mutant enzyme at 42°C for 1 0 minutes, 80% of the enzyme activity was EREDITARY methemoglobinemia is an autosomal H recessive disorder that may arise from the deficiency of NADH cytochrome b5 reductase (b5R, EC 1.6.2.2). This enzyme is an flavin adenine dinucleotide (FAD)-containing flavoprotein that catalyzes the transfer of two electrons from NADH to two molecules of cytochrome b5 via enzyme-bound FAD.'s2 Two forms of the enzyme, soluble and membrane bound, are known. The former exists in erythrocytes and plays a role in methemoglobin red~ction.~ The latter is bound to endoplasmic reticulum and on the outer mitochondrial membrane of somatic cells and participates in the elongation and desaturation of fatty cholesterol biosynthesis,6 and drug metabolism.'. ' To investigate a molecular mechanism leading to various types of hereditary methemoglobinemia, we have purified' and determined" the amino acid sequence of the soluble form of the enzyme, isolated cDNAs from human liver and placenta,' ' sequenced the human b5R gene,12 and constructed a bacterial expression system from which we can obtain the soluble form of the enzyme with an authentic primary structure.13 These studies showed that the membrane-bound form consists of two portions. One is the catalytic portion with 275 amino acids whose primary structure is the same as that of the soluble form in erythrocytes and the other is the NH2-terminal membrane binding portion, comprising a 25 amino acid-hydrophobic stretch and a covalently linked myristoyl group to NH2-terminus.'4 The soluble form of enzyme is generated from the same gene as for the membrane-bound form either by proteolytic processing of the membrane bound
or by a direct translation from erythroid-specific form '2. I5 transcript that codes for NH2-terminal portion of the soluble form, as recently demonstrated in the rat. I6 Hereditary methemoglobinemia caused by b5R deficiency is classified as three types: an erythrocyte type (type I)," a generalized type (type II),'* and a blood cell type (type III).I9
In type I, functional enzyme deficiency is restricted to erythrocytes, and, therefore, these patients manifest only grayish cyanosis caused by elevated methemoglobin. We have recently identified the missense mutations in the gene of three unrelated probands of type I and characterized the respective recombinant mutant enzymes2' The enzymes have 60% to 70% of the activity of the wild type and are heat labile, indicating that a restriction of enzyme deficiency to erythrocytes is caused by a degradation of unstable mutant enzymes in the patients' erythrocytes during the long life span with no compensation by new protein synthesis. Some extent of decrease in the activity in blood cells other than erythrocytes in patients with type I was observed in concert with the results obtained from the characterization of the recombinant enzymes.
In type 11, the deficiency occurs in all tissues and is associated with mental and growth retardation in addition to cyanosis. Our recent analysis on the recombinant type I1 enzyme, Ser-127 + Pro, showed that the enzyme has a low haJK, value compared with type I mutants whose values are closer to normal.2' In type 111, the deficiency has been reported" to be observed in all blood cells (eg, leukocytes, platelets, and erythrocytes), and patients with type I11 manifest similar symptoms to patients with type I. The molecular mechanism leading to this puzzling pattern of enzyme deficiency has been a subject of controversy. Katsube et a1 reported that the b5R gene of patients with hereditary methemoglobinemia type 111 found in Kurobe has a T to C transition at codon 148, which results in the production of an enzyme with proline instead of leucine at residue 148. 22 In the present study, we have prepared and characterized the mutant enzymes in which Leu-148 has been replaced by Pro (L148P) or by Ala (L148A), utilizing site-directed mutagenesis and an expression systemr3 for the soluble form of the enzyme in Escherichia coli. This study was undertaken in an attempt to analyze the molecular details of the mutant enzyme produced in patient tissues, to understand how the use only. 
MATERIALS AND METHODS
Materials. Restriction endonucleases and T4 polynucleotide kinase were purchased from Takara Shuzo Co (Kyoto, Japan). [a-35S]deoxycytidine triphosphate (dCTP) (> 1,000 Ci/mmol) and an in vitro oligonucleotide-directed mutagenesis system were products of Amersham (UK). Sequenase DNA sequencing kit was obtained from US Biochemical (Cleveland, OH). Oligonucleotides for mutagenesis were synthesized with a Model 8600 DNA synthesizer (Biosearch, San Rafael, CA). Diethyl aminoethyl (DEAE)-Toyopearl used for enzyme purification was the product of Tosoh (Tokyo, Japan) and 5'-AMP-Sepharose 4B and Sephacryl S-200 were products of Pharmacia (Uppsala, Sweden). Amphotericin B and (p-amidinopheny1)methane-sulfonyl fluoride hydrochloride (A-PMSF) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Prestained molecular weight markers were obtained from Bio-Rad (Richmond, CA). All other chemicals were of reagent grade.
Studies were performed on the patient, M.N., who was described by Tanishima et al as a case of hereditary methemoglobinemia type III.I9 In brief, he is a 29-year-old Japanese man with a grayish cyanosis but without mental or neurologic abnormalities. The clinical presentations and hematologic data have been described previously. l9 Heparinized venous blood samples obtained from the patient and normal subjects were fractionated within 48 hours. Blood samples were at first centrifuged at 300g for 5 minutes. Supernatant fractions of the blood samples were carefully collected to prevent contamination by red blood cells, diluted two-fold with phosphate-buffered saline (PBS), and overlayed on a leukocyte separation medium, Histopaques, obtained from the Sigma Chemical Co (St Louis, MO) consisting of 10 mL each of Histopaque-IO77 (upper layer) and Histopaque-I 119 (lower layer). Platelet-rich layers and lymphocyte-rich layers were obtained after centrifugation at 600g for 30 minutes (at 4"C), and 3 vol of PBS were added to each layer. After centrifugation at 500g for 10 minutes, pellets were washed with PBS and centrifuged at 500g for 10 minutes. The resulting pellets were suspended in 0.28% (wt/vol) NaCl to disrupt the small number of contaminating red blood cells and were washed again. Sedimented platelets and lymphocytes were stored at -80°C for later use.
Skin samples obtained from the patient's arm and from healthy males were cut into small pieces (1 X 1 mm) by surgical knives and cultured at 37°C for about 4 weeks in Dulbecco's Modified Eagle's Minimum Essential Medium (NISSUI, Tokyo, Japan) supplemented with 10% fetal bovine serum (FBS GIBCO, Grand Island, NY), 100 U/mL of penicillin, 0.1 mg/mL of streptomycin, and 2.5 pg/mL of Amphotericin B in a humidified atmosphere containing 5% C02. Skin fibroblasts thus cultivated were treated with 0.25% (wt/vol) trypsin in PBS to remove them from the culture flask. Cells were harvested by centrifugation at 250g for 5 minutes. The resulting pellets were washed once with PBS containing 1 mmol/L CaC12 and 1 mmol/L MgClz and were stored at -80°C for later use.
Enzyme activity was assayed by following the increase in absorbance at 424 nm caused by the reduction of recombinant human erythrocyte cytochrome b5 in the presence of NADH as an electron donor as described previously? In this assay system, electrons are transferred from NADH to cytochrome 6, via 
, 0.5% Triton X-100, 10 pmol/L A-PMSF, and 10 pmol/L pepstatin and were then placed on ice for 20 minutes. After centrifugation at 20,OOOg for 2 minutes, the supernatant fraction was used as the enzyme solution. NADH cytochrome b, reductase activity was measured in a reaction mixture (2 mL) containing 5 mmol/L TRIS HC1 (pH 7.9, 2 pmol/L human erythrocyte cytochrome b5, 100 pmol/L NADH, and 0.05% Triton X-100. The reaction was started by the addition of 5 to 10 pL of enzyme solution.
The HindIII-PstI fragment (503 bp), which includes the NH2-terminal portion of b5R cDNA, was excised from expression plasmid placZ'-APR-b,-R" and cloned into HindIIIPstI site of M13mp19. Synthetic antisense oligonucleotides were used to alter the Leu-148 codon (CTG) to one coding for proline (CCG): 5'-CTGGTAGACCC_GCAGCCCACT-3' and alanine (GCG): 5'-CTGGTAGACCGXCAGCCCACT-3' (the underlined bases were exchanged). Mutants generated with these oligonucleotides were named LI 48P and L 148A, respectively. Site-directed mutagenesis was performed by the strand selection method of Taylor et using the Amersham mutagenesis system. M 13 phage single-strand DNA was prepared from four independent plaques and mutant clones were selected by dideoxy sequencingz5 Nucleotide sequences of the HindIII-PstI fragments were verified. The mutated HindIII-PstI fragments were excised from the mutant M 13 phage DNA and cloned into pUC-b,R/B to construct the mutant expression pla~mid.'~.~' Mutant forms of b5R were expressed in E coli RB791 and purified as described previously as an a-thrombin-cleavable fusion protein. 13 For the wild type and L148A, a-thrombin treatment to obtain the authentic soluble form of the enzymes was camed out as described previo~sly.'~ Because L148P showed a significant decrease in the catalytic activity by the treatment, a-thrombin digestion was not performed for the mutant. Therefore, L148P was purified as a fused protein having extra 1 1 amino acid residues at the NH2-terminus. 13 The kinetic values of L148P can be compared with that of the wild type because kinetic properties of the wild type do not change before and after the athrombin treatment (data not shown). Enzyme activity 0fb5R during purification was monitored by assaying NADH-femcyanide reductase activity. The activity was measured by following the absorbance change at 420 nm at 25°C using a difference in absorption coefficient of the oxidized and reduced compounds, 1 (mmol/L)-' . cm-'. The standard reaction contains 100 pmol/L NADH, 0.5 mmol/L potassium femcyanide, an appropriate amount of enzyme, and IO mmol/ L potassium phosphate, pH 7.5. The enzyme concentration was determined on the basis of the absorption coefficient of FAD at 450 nm ( Western-blotting analysis of bSR in crude enzyme solutions of blood cells and fibroblasts was performed as described by Hawkes et al,31 using rabbit anti-serum against HE b,R and peroxidase-conjugated anti-rabbit IgG. The b5R was detected on the membrane by color development using 4-chloro-I-naphthol and HZ02 as the substrates of the peroxidase conjugated to the second antibody.
RESULTS

Western-blotting analysis.
Preparation of the recombinant mutant enzymes. L148P mutant was prepared and characterized using the expression system in E coli and site-directed mutagenesis to examine whether the phenomena occurring in the patient could be attributed to the base change identified before. 22 Because we have noticed a heat instability of L148P mutant, a-thrombin treatment was not performed for the mutant. Preparation of L148A was also achieved to clarify the role of the residue in enzyme function. Yield of the mutant enzymes during purification was 3.4% for L148P and 48.2% for L148A. From a I-L culture of E coli, about 80,6, and 59 mg ofthe purified b,Rs were obtained for the wild type, L148P, L148A, respectively. The wild-type and L148A mutant enzymes were purified to homogeneity as judged by SDS-polyacrylamide gel (12.5%) electroph~resis,~~ whereas the purity of L148P was 83% as determined by the difference between the amount of the enzyme estimated by FAD content and that of protein determined by the method of Lowry et al. 27 The kinetic properties of the mutant enzymes are summarized in Table 1 . The Km value of L148P for cytochrome bj was about 1.5-fold higher than that of the wild type, whereas the value for NADH was unchanged. The k,, value of L148P was about 60% of the value of the wild type. Values of kJK, (NADH) and kaJ K, (cytochrome b,) for L148P were 47% and 38% of the value of the wild type, respectively. Kinetic properties of L148A were almost the same as those of the wild type except that ha, value of the mutant was about 90% of that of the wild type.
When the diluted bjRs (10 pmol/L, 0.32 mg/mL) were incubated for IO minutes at various temperatures, the distinct differences in heat stability of mutant enzymes and the wild type were observed (Fig IA) . Residual activities of L148P after a 10-minute incubation at 37°C and 42°C were about 70% and ~2 0 % of the initial activity, respectively. In contrast, the wild type retained >90% of the initial activity at 50°C. The heat stability of L148A was intermediate between the wild type and L148P. Although the wild type was very stable at 42°C (almost 100% activity after 30 minutes), L148P was heat inactivated rapidly to 4 % of the initial activity under the same conditions (Fig 1B) . L148A retained almost 80% of the initial activity. From the results mentioned above, we question the validity of the former report" and reinvestigated the activities of blood cells and fibroblasts from the patient. Specific b5R activities of lymphocytes, platelets, and fibroblasts were 52.5 nmol/min/ mg, 94.5 nmol/min/mg, and 64.6 nmol/min/mg, respectively. In contrast to the previous report,'' enzyme activity of blood cells and fibroblasts determined in this study were about 40% of the normal activity of these cells (Table 2) .
To determine whether or not fibroblasts, lymphocytes, and platelets from the patient express b5R protein at a detectable level, Western blotting analysis was performed (Fig 2) . As shown in Fig 2, (Table I) . A remarkable characteristic of L148P determined in this study is its heat instability. More than 80% ofactivity was lost after incubation at 42°C for IO minutes (Fig IA and B) , whereas the wild type loses less than 20% activity after incubation at 50°C for 30 minutes?' One of the important purposes of this study is to clarify the puzzling reported observation that this mutation resulted in a specific deficiency of the enzyme in blood cells (white blood cells and platelets as well as erythrocyte^)?^ Because this pattern of enzyme deficiency will not be able to be explained by the recent identification of the mutant in the coding we reinvestigated carefully the enzyme activities in the lymphocytes, platelets, and fibroblasts of the Kurobe patient with type 111 hereditary methemoglobinemia. In con- 
to the previous report, significant activities, about 40% of the normal, were detected in all these cells (Table 2) . Furthermore, by the Western blotting analysis, the amounts of bSR protein detected in the blood cells and fibroblasts of the patient were comparable to those detected in a normal control (Fig 2) . These results suggest that the failure in detecting the enzyme activity in blood cells in the previous report" was caused by the inactivation of the enzyme during the sample processing. The fact that the mutant enzyme was equally expressed in lymphocytes, platelets, and fibroblasts is consistent with the finding of missense mutation in the coding region, not in the regulatory region, of the gene in this patient.
We have recently analyzed the base sequences of the gene in three independent probands of type I and identified two different mutant alleles in the patients that result in single amino acid substitutions, Arg-57-tGln and Val-105+Met2'
As discussed previously," the k, JKm value is a good indicator of catalytic efficiency in vivo and the value of Leu-l48+Pro is 47% of the normal. This is rather higher than those of type I mutant enzymes ( Table 3 ). In contrast, the value of type I1 mutant enzyme, Ser-127-tPr0, is 3.4% of the normal, which is distinctly lower than those of type I enzymes and may not be sufficient for cell functions.
Because in the earlier stage of the studies on hereditary methemoglobinemia the activities in the patients' tissues are based on NADH-diaphorase activity using artificial dyes, such as 2,6-dichloroindophenol as an electron acceptor that covers activities of various reductases in addition to b5R,34 it is likely that a partial decrease in b5R activity in the tissues other than erythrocytes in patients with type I had been overlooked. The recent measurements of the enzyme activity using cytochrome bS performed by ourselves,20 as summarized in Table 3 and by other g r o~p s ,~~,~~ showed that a decrease in the activity does occur in blood cells other than erythrocytes in patients with type I. These results are consistent with our finding that type I disease is caused by missense mutations that result in instability and somewhat impaired activity of the enzyme. Therefore, the patient would be associated with general symptoms only when the enzyme activity in somatic cells is reduced to a level that is not sufficient for the various metabolic pathways in which the enzyme is involved. In contrast, in patients with type I, the functional enzyme deficiency occurs only in erythrocytes where there can be no compensation by new protein synthesis during its long life span because these patients have unstable variant enzymes with relatively high catalytic efficiency. As shown in Table 3 , the enzyme activity of various cells of the Kurobe patient is in the range of type I rather than type 11.
Consequently, the patient analyzed in the present study should be classified into type I, considering his symptoms, the similar kinetic properties of Leu-148-tP1-o mutant enzyme to those of the type I mutants analyzed in the former study, and activities in blood cells and fibroblasts. Though Arnold et a1 reported in abstract form a German family of type 111,37 the data have not been published and the details are unknown. Because, at present, a detailed report on type 111 hereditary methemoglobinemia is only available for the family in Kurobe, Japan, it seems now unnecessary to have a "type 111" classification in this disease.
The majority of the patients with hereditary methemoglobinemia have only asymptomatic cyanosis, whereas about 10% of these patients have associated severe general symptoms, including mental and growth retardation in addition to cyanosis. For most of these patients, it may be possible to categorize them into either erythrocyte-restricted type (type I) or generalized type (type 11) on the basis of mental development. When methemoglobinemic cyanosis is noted in the neonatal stage, it would be feasible to predict if the patient will undergo normal mental development by determining whether or not the enzyme activity is severely impaired (to around 10% of normal) in the tissues other than erythrocytes. The activity of lymphocytes and platelets can be used to determine the prognosis of the methemoglobinemic newborns because the low activity of the enzyme in those cells would be linked to general symptoms including neurological disorders as shown in this study. Thus, also from clinical aspects, hereditary methemoglobinemia caused by hsR deficiency W e have constructed a n d purified L148A as well as L148P in order to determine the role ofthe leucine-148 in the enzyme function. Catalytic properties of the L148A mutant enzyme were almost the same as those of the wild type as observed for L148P mutant. Thus, Leu-148 was shown not to be involved in the catalytic function of the enzyme. These results are consistent with the expectation that this residue resides in the linker region. L148A is much more stable than L148P but is more heat labile than the wild type, suggesting that Leu-148 might play a role(s) i n maintaining the native structure of the enzyme. Replacement at position 148 with a proline, which provides a fixed dihedral angle to the main chain, may cause a structural disturbance leading to a more unstable mutant enzyme. Because Leu-148 of b5R is replaced only by hydrophobic amino acids such as an isoleucine, a valine, or a phenylalanine in nitrate reductase^,^^ hydrophobicity at position 148 may be critical for the maintenance of the structure of b5R and nitrate reductases. T h e x-ray crystallographic analysis, now pr0gressing,4~ will lead us to further understanding of the role of Leu-148.
